Next Article in Journal
Superhydrophobicity Effects on Spheroid Formation and Polarization of Macrophages
Previous Article in Journal
Anthocyanin-Rich Fraction of Black Rice Bran Extract Protects against Amyloid β-Induced Oxidative Stress, Endoplasmic Reticulum Stress, and Neuronal Apoptosis in SK-N-SH Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 8
10.3390/ph17081040
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile

by
Mariana Vieira Morau
1,
Cecilia Souto Seguin
1,
Mauricio Wesley Perroud Junior
1,
Carolina Dagli-Hernandez
2,
Eder de Carvalho Pincinato
1 and
Patricia Moriel
2,*
1
Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas 13083-887, SP, Brazil
2
Faculdade de Ciências Farmacêuticas, Universidade Estadual de Campinas, Campinas 13083-871, SP, Brazil
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(8), 1040; https://doi.org/10.3390/ph17081040
Submission received: 5 June 2024 / Revised: 31 July 2024 / Accepted: 6 August 2024 / Published: 7 August 2024
(This article belongs to the Special Issue Pharmacogenomics for Precision Medicine)
Browse Figure
Review Reports Versions Notes

Abstract

:
Gefitinib is a selective inhibitor of the epidermal growth factor receptor that is used to treat advanced and metastatic non-small cell lung cancer (NSCLC). Dermatological adverse reactions are most commonly associated with gefitinib treatment. The cause of adverse reactions in individuals is multifactorial. Pharmacogenetics is an effective tool to detect such adverse reactions. This case report describes a female patient with NSCLC who was administered gefitinib at a dose of 250 mg/day. However, due to severe adverse dermatological reactions, the treatment was interrupted for 15 d and antibiotic therapy was administered to manage the skin rashes, maculopapular rashes, and hyperpigmentation. Treatment adherence was adequate, and no drug interactions were detected. A pharmacogenetic analysis revealed homozygosity in the ATP-binding cassette (ABC)-B1 rs1128503 (c.1236A>G), heterozygosity in ABCG2 rs2231142 (c.421G>T) and rs2622604 (c.-20+614T>C), and a non-functional variant of the cytochrome P450 family 3, subfamily A, member 5 (CYP3A5). The relationship between altered genetic variants and the presence of adverse reactions induced by gefitinib is still controversial. Overall, this case report highlights the importance of continuing to study pharmacogenetics as predictors of adverse drug reactions.

1. Introduction

Gefitinib is a potent oral and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) [1]. It is an effective therapeutic agent for non-small cell lung cancer (NSCLC) associated with active mutations in EGFR, mainly in exons 19 (deletion) and 21 (L858R) [2]. TKI-EGFR is commonly associated with dermatological adverse events (AEs; observed in almost 50% of the patients), as EGFR is expressed in the basal layers of epidermal keratinocytes and hair follicles, where it plays essential roles in cell structure maintenance and proliferation [3,4].
The main dermatological clinical manifestations include rashes, maculopapular rashes, and paronychia. These AEs occur due to EGFR blockade, which leads to endothelial inflammation, reduced vascular tone, and consequently, increased vascular permeability [5]. Therefore, dermatological manifestations are secondary adverse drug reactions, that is, with predictable and non-immunological effects, thus differentiating themselves from allergic and hypersensitivity reactions [6,7].
Gefitinib is extensively metabolized in the liver, predominantly by the cytochrome P450 (CYP) enzyme, CYP3A4, and moderately by CYP3A5 and CYP2D6. Its transport out of the cells is dependent on ATP-binding cassette (ABC) transporters, such as ABCG2 (BCRP/MRP) and ABCB1 (P-glycoproteins/MRD1) [8,9]. Pharmacogenetic studies on the single-nucleotide polymorphisms (SNPs) of CYP enzymes and ABC transporters have revealed the important pharmacokinetic and pharmacodynamic differences between them, possibly responsible for the occurrence of AEs [10,11,12,13]. Human leukocyte antigen (HLA)-A and -B have also been analyzed to assess the possible influence of HLA genotypes on the response to antineoplastic treatments [14].
Here, we present a case report of a female patient with NSCLC who experienced severe adverse dermatological events after gefitinib treatment. We investigated whether the patient carried any variants in the genes involved in the pharmacogenetics of gefitinib and analyzed the drug–drug interactions that could have led to the observed AEs.
This study is reported in accordance with the CARE Guidelines and Checklist available on the CARE website (www.care-statement.org) and EQUATOR Network (www.equator-network.org) (accessed on 10 May 2024).
Written informed consent was obtained from the patient for the publication of this case report and any accompanying images.

2. Results

A 55-year-old Caucasian woman was admitted to the OncoPneumology Ambulatory of a public hospital at UNICAMP (Campinas, São Paulo, Brazil) in March 2022. She was diagnosed with adenocarcinoma of the right lung with metastasis to the mediastinal lymph nodes, liver, and bone. Genetic tests for EGFR showed that the patient had a mutation in L858R in exon 21, after which she was prescribed gefitinib at 250 mg/day.
The patient did not smoke at the time but had been a passive smoker for approximately 10 years. No alcoholism or other comorbidities were reported. The patient did not have a history of hypersensitivity reactions to drugs. Other medications used at the time of gefitinib prescription included metamizole (500 mg) for pain control, doxycycline twice daily, and estriol ointment prescribed by an outside gynecologist for a urinary infection.
After 4 weeks of gefitinib treatment, the patient developed an acneiform rash on the face and scalp, with hyperpigmentation on the face (Figure 1a). Topical clindamycin and hydrocortisone were prescribed for AEs, and gefitinib treatment was not interrupted.
Adverse dermatological reactions worsened significantly after 10 weeks of gefitinib treatment. The patient exhibited pustules and papules on her face and maculopapular and acneiform eruptions, which was characterized as grade 3 according to the Common Terminology Criteria for Adverse Events (CTCAE) [15] (Figure 1b,c). At this point, treatment with gefitinib was discontinued for 15 days, and antibiotic therapy with tetracycline (1 g) was initiated twice daily. As shown in Figure 1d–f, a slight improvement in adverse reactions was observed 7 d after gefitinib interruption and initiation of oral tetracycline therapy.
After interruption of the targeted therapy, the patient returned to the ambulatory state with significant improvement in skin lesions (Figure 1g–i). Therefore, gefitinib was reintroduced (250 mg/day), and tetracycline treatment was continued at 500 mg twice daily.
In November 2022, 8 months after starting gefitinib treatment, the patient reported improvement in rashes on her face. However, acneiform rashes appeared on the abdomen and right and left sides of the costal region (Figure 1j–m).
To identify the possible predisposing genetic polymorphisms contributing to the etiology of these serious adverse reactions, the following genes encoding enzymes and transporters involved in the pharmacokinetics and pharmacodynamics of gefitinib were investigated: EGFR, ABCB1, ABCG2, CYP2D6, CYP3A4, CYP3A5, and HLA. Analyses were performed by microarray using the Infinium Global Diversity Array with Enhanced PGx (iSan Illumina, San Diego, CA, USA).
The patient reported adherence to treatment. According to the Brief Medication Questionnaire (BMQ) and MEDTAKE [16,17,18], the patient did not forget her medications (100% adherence).
The results of the genetic tests are shown in Table 1. In drug transporters, the patient is homozygous for ABCB1 rs1128503 (c.1236A>G) and heterozygous for ABCG2 rs2231142 (c.421G>T) and rs2622604 (c.-20+614T>C). The genotypes of the CYP enzymes were CYP2D6 *1/*2 and CYP3A5 *3/*3 (rs776746, c.219-237T>C). She did not carry any variants in CYP3A4 or EGFR, nor did she carry any variants in HLA types.
Next, we investigated whether drug–drug interactions cause AEs. We identified doxycycline as a possible inhibitor of CYP3A4 [19], which is the main enzyme metabolizing gefitinib.

3. Discussion

EGFR inhibitors are often used as monotherapies or in combination with radiotherapy for the treatment of solid tumors, such as lung, colorectal, and pancreatic cancers [20]. NSCLC is the most common subtype of lung cancer, accounting for 80–85% of all cases [21]. Gefitinib is a first-generation selective EGFR inhibitor used for patients with advanced and metastatic NSCLC; it is well tolerated orally, but some adverse reactions have been reported [22].
Most adverse reactions associated with the use of gefitinib are linked to the integumentary, gastrointestinal, and hepatic systems, the vast majority of which are mild to moderate in nature (grade 1–2 according to the CTCAE) [15,23]. Dermatological AEs, especially acneiform and maculopapular rashes (mainly in the face, chest, neck, and back; 47% of patients) and dry skin (13%), are among the most common adverse reactions (50–55% of patients) [21,22,23,24]. Some studies have also reported adverse nail reactions, such as paronychia and onychocryptosis [9,25,26], and a few have reported alopecia [27,28].
Some studies have reported dermatological adverse reactions, such as severe and extensive skin rashes with redness and aspparent swelling requiring the discontinuation of gefitinib [29] as well as rashes with scaly crusts on the face requiring the cessation of TKIs [30]. However, to date, no study has investigated the association of pharmacogenetics with the occurrence of adverse reactions.
Here, the patient was a homozygous carrier of the CYP3A5*3 (rs776746, c.219-237T>C) variant, which results in enzyme inactivity [31]. A study in healthy individuals showed that this polymorphism, once detected, directly alters the pharmacokinetics of gefitinib, specifically its clearance [32]. On the other hand, a study in individuals with NSCLC suggested that this polymorphism in CYP3A5 would not be associated with adverse reactions induced by gefitinib, much less with plasma levels of the drug. However, the CYP3A4*1/*1G variant, for which the patient was not a carrier, is associated with this risk of toxicity [33]. CYP3A5 and CYP3A4 share 83% similarity in their amino acid sequences, possessing significant structural homology [31].
Gefitinib metabolism is quite extensive and complex [34]. An in vitro study comparing TKIs showed that gefitinib is more susceptible to metabolism by CYP3A5, which may contribute to higher clearance [10]. However, another in vitro study with human liver microsomes inferred that CYP3A5 has much lower catalytic activity (about 12%) towards gefitinib compared to CYP3A4 [35]. To date, only one study in patients with NSCLC has shown that a poor metabolizer profile in CYP3A5 can predict ADR, particularly hepatotoxicity [36]. CYP3A5*3 impairs the elimination of gefitinib; nevertheless, there is controversy over whether it can cause adverse reactions induced by gefitinib.
ABCB1 or MDR1 encodes the P-glycoprotein (P-gp) region containing approximately 124 SNPs [37] that have been abundantly studied owing to their important roles in drug efflux [38]. This protein is expressed in the liver, kidneys, and lungs [39]. Here, the patient carried the GG genotype of ABCB1 rs1128503 and presented with severe skin reactions. Preemptive genotyping of some ABCB1 SNPs, rs1128503 (c.1236A>G) in this case, can help to reduce the adverse reactions to chemotherapy drugs [40]. In colorectal cancer, capecitabine-treated patients with GG genotype exhibit a higher risk of neutropenia or hand–foot syndrome compared to those with AA genotype [41]. However, some studies on gefitinib have reported otherwise. A study of Chinese patients with NSCLC revealed that the GG genotype reduces the risk of diarrhea and skin rashes on gefitinib treatment [42]. In contrast, a systematic review with meta-analysis carried out by our group [43] demonstrated possible clinical implications of ABCB1 rs1128503 (c.1236A>G) in gefitinib-induced rash and diarrhea reactions. Therefore, the skin reactions observed in our patient may have been caused by this variant.
ABCG2 is an important gene involved in the efflux of several drugs, including gefitinib [44]. Here, the patient was heterozygous for both ABCG2 rs223142 (421G>T) and rs2622604 (c.-20+614C>T). The consequences of these polymorphisms have not yet been fully elucidated, but one study showed that individuals carrying the GT genotype of the 421G>T (rs223142) polymorphism exhibit an increased risk of diarrhea compared to those with the GG genotype after gefitinib treatment [45]. However, a study with patients with NSCLC did not find associations with the T allele (heterozygous or homozygous) and gefitinib reactions [46]. The presence of adverse reactions, such as skin reactions or diarrhea, can be explained by the roles of transporters in the oral absorption and elimination pathways of gefitinib, as ABCG2 is highly expressed in the intestine and liver [47]. A meta-analysis study that investigated the associations of ABCG2 genes and gefitinib toxicities showed that rs rs223142 (421G>T) may not be a reliable biomarker of dermatological toxicity induced by gefitinib [48]. Thus, the association of ABCG2 rs223142 in the current patient is questionable and warrants further investigation with additional cases.
CYP genes are highly polymorphic. Failure or low activity of CYP enzymes [49] and genetic copy number variations (CNVs) [50] increase the risk of adverse reactions. Reduced CYP2D6 function (*10/*10) is associated with an increased risk of grade ≥2 skin rashes [43,51]; however, patients with CYP2D6 metabolizing genes exhibit a normal genotype, CYP2D6*1/*2, with a CNV of 2.
HLA genes, despite not being closely related to the metabolism of gefitinib, were investigated in this study, as they have high germinal and somatic heterogeneity and influence the therapy of patients’ cancer [14]. Patients with cancer who are homozygous for HLA class I exhibit reduced responses to checkpoint inhibitors [52]. However, in this study, the patient exhibited a normal HLA genotype.
Whether non-genetic factors, such as drug–drug interactions, lead to adverse reactions warrants further investigation. Here, the patient was treated with doxycycline, metamizole, and estriol ointments when the gefitinib treatment was initiated. An in vitro study demonstrated that doxycycline induces CYP3A4 [19]. As gefitinib is also metabolized by CYP3A4, this could be a possible mechanism of drug–drug interaction. However, no other studies support this finding, and no evidence of the interactions between doxycycline and gefitinib is currently available. Therefore, we excluded the possibility of drug–drug interactions in this study.
This study has some limitations. As this is a case report, it does not indicate a representative sample of the population; however, it highlights the importance of pharmacogenetic studies in predicting adverse drug reactions. The plasma concentration of gefitinib in this patient was within the expected therapeutic window, as it was orally administered. Moreover, the patient adhered to the medication plan.

4. Conclusions

Here, our findings showed a case of a patient with NSCLC, using gefitinib, doxycycline, and metamizole, plus homozygosity in ABCB1 rs1128503 (c.1236A>G), heterozygosity in ABCG2 rs2231142 and rs2622604 (c.421G>T+c.-20+614T>C), and the presence of a non-functional component in the CYP3A5 variant, and the presence of moderate to severe adverse reactions associated with the use of gefitinib.
There are several controversies about the contribution of these variants in the adverse reactions presented by the patient. However, we highlight the hypothesis that the ADRs induced by gefitinib may be caused by the non-functional variant of CYP3A5*3 and in the homozygous variant of ABCB1 (rs1128503). We emphasize the importance of continuous study of pharmacogenetic analyses in predicting individual responses to treatment, particularly concerning adverse drug reactions. This is essential for advancing research on genetic variants as potential risk biomarkers.

Author Contributions

Conceptualization, M.V.M., C.S.S., M.W.P.J. and P.M.; methodology, M.V.M., P.M. and E.d.C.P.; software, P.M. and E.d.C.P.; formal analysis, P.M. and E.d.C.P.; investigation, M.V.M., M.W.P.J. and P.M.; resources, P.M. and E.d.C.P.; data curation, M.V.M., E.d.C.P. and P.M.; writing—original draft preparation, M.V.M. and C.D.-H.; writing—review and editing, M.V.M., C.D.-H. and P.M.; supervision, P.M.; funding acquisition, P.M. and E.d.C.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Council for Scientific and Technological Development (CNPq) (14030/2019-4; 444090/2023); the São Paulo Research Foundation (FAPESP) (2023/06280-7); the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brazil (CAPES) (Finance Code 001); and Pharmaceutical Security Nucleus Project, object of Agreement no. 895688/2019, the result of a partnership between the Ministry of Justice and Public Security of Brazil, through the Fund for the Defense of Diffuse Rights and the State University of Campinas.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by Ethics Committee of Faculdade de Ciências Médicas da Universidade Estadual de Campinas-Unicamp—(protocol code 17328619.90000.5404, 30 August 2019).

Informed Consent Statement

Informed consent was obtained from the patient involved in the study.

Data Availability Statement

The data presented in this study are openly available in Patricia Moriel, 2024, “Replication Data for: Influência das variantes genéticas (SNPs) e da concentração plasmática de gefitinibe nas reações adversas e sobrevida de pacientes com câncer de pulmão de não pequenas células”, https://doi.org/10.25824/redu/DPBPXU, Repositório de Dados de Pesquisa da Unicamp.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; McGuinn, W.D.; Morse, D.; Abraham, S.; Rahman, A.; Liang, C.; Lostritto, R.; et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 2004, 10, 1212–1218. [Google Scholar] [CrossRef] [PubMed]
  2. Mok, T.; Yang, J.-J.; Lam, K.-C. Treating Patients with EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference? J. Clin. Oncol. 2013, 31, 1081–1088. [Google Scholar] [CrossRef]
  3. Pastore, S.; Lulli, D.; Girolomoni, G. Epidermal growth factor receptor signalling in keratinocyte biology: Implications for skin toxicity of tyrosine kinase inhibitors. Arch. Toxicol. 2014, 88, 1189–1203. [Google Scholar] [CrossRef] [PubMed]
  4. Hofheinz, R.-D.; Deplanque, G.; Komatsu, Y.; Kobayashi, Y.; Ocvirk, J.; Racca, P.; Guenther, S.; Zhang, J.; Lacouture, M.E.; Jatoi, A. Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients with Solid Tumors. Oncologist 2016, 21, 1483–1491. [Google Scholar] [CrossRef] [PubMed]
  5. Li, Y.; Fu, R.; Jiang, T.; Duan, D.; Wu, Y.; Li, C.; Li, Z.; Ni, R.; Li, L.; Liu, Y. Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies. Front. Oncol. 2022, 12, 804212. [Google Scholar] [CrossRef]
  6. Nayak, S.; Acharjya, B. Adverse cutaneous drug reaction. Indian J. Dermatol. 2008, 53, 2–8. [Google Scholar] [CrossRef]
  7. Pichler, W.J. Immune pathomechanism and classification of drug hypersensitivity. Allergy 2019, 74, 1457–1471. [Google Scholar] [CrossRef] [PubMed]
  8. Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J.; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003, 290, 2149–2158. [Google Scholar] [CrossRef]
  9. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.-Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; et al. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients with Advanced Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2003, 41, 1162–1171. [Google Scholar] [CrossRef]
  10. Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S.D. Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clin. Cancer Res. 2007, 13, 3731–3737. [Google Scholar] [CrossRef]
  11. Tamura, M.; Kondo, M.; Horio, M.; Ando, M.; Saito, H.; Yamamoto, M.; Horio, Y.; Hasegawa, Y. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (abcg2, abcb1) and gefitinib toxicity. Nagoya J. Med. Sci. 2012, 74, 133–140. [Google Scholar] [CrossRef] [PubMed]
  12. Luo, H.; Qin, G.; Yao, C. Correlation between adverse events after drug treatment and the MDR1 C3435T polymorphism in advanced non-small cell lung cancer patients in an Asian population: A meta-analysis. J. Int. Med. Res. 2019, 47, 3522–3533. [Google Scholar] [CrossRef]
  13. Wan, Z.; Guo, L.; Li, P.; Zhao, Z.; Xu, B.; Ren, L.; Yan, Y.; Liu, H.; Zhang, Y.; Liu, L. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters. J. Clin. Pharm. Ther. 2020, 45, 1159–1167. [Google Scholar] [CrossRef] [PubMed]
  14. Pagliuca, S.; Gurnari, C.; Rubio, M.T.; Visconte, V.; Lenz, T.L. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond. Front. Immunol. 2022, 13, 944872. [Google Scholar] [CrossRef] [PubMed]
  15. U.S Department of Health and Human Services; National Institute of Health NCI; U.S Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE); Version 5.0. 2018. Available online: https://nciterms.nci.nih.gov/ncitbrowser/pages/vocabulary.jsf?dictionary=CTCAE_v5&version=5.0 (accessed on 10 May 2024).
  16. Raehl, C.L.; Bond, C.A.; Woods, T.; Patry, R.A.; Sleeper, R.B. Individualized Drug Use Assessment in the Elderly. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2002, 22, 1239–1248. [Google Scholar] [CrossRef]
  17. Horne, R.; Weinman, J.; Hankins, M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol. Health 1999, 14, 1–24. [Google Scholar] [CrossRef]
  18. Salgado, T.; Marques, A.; Geraldes, L.; Benrimoj, S.; Horne, R.; Fernandez-Llimos, F.; Salgado, T.; Marques, A.; Geraldes, L.; Benrimoj, S.; et al. Cross-cultural adaptation of the Beliefs about Medicines Questionnaire into Portuguese. Sao Paulo Med. J. 2013, 131, 88–94. [Google Scholar] [CrossRef]
  19. Yasuda, K.; Ranade, A.; Venkataramanan, R.; Strom, S.; Chupka, J.; Ekins, S.; Schuetz, E.; Bachmann, K. A Comprehensive in Vitro and in Silico Analysis of Antibiotics That Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine. Drug Metab. Dispos. 2008, 36, 1689–1697. [Google Scholar] [CrossRef]
  20. Rocha-Lima, C.M.; Soares, H.P.; Raez, L.E.; Singal, R. EGFR targeting of solid tumors. Cancer Control 2007, 14, 295–304. [Google Scholar] [CrossRef]
  21. Molina, J.R.; Yang, P.; Cassivi, S.D.; Schild, S.E.; Adjei, A.A. Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin. Proc. 2008, 83, 584. [Google Scholar] [CrossRef] [PubMed]
  22. Birnbaum, A.; Ready, N. Gefitinib therapy for non-small cell lung cancer. Curr. Treat. Options Oncol. 2005, 6, 75–81. [Google Scholar] [CrossRef]
  23. Cersosimo, R.J. Gefitinib: An adverse effects profile. Expert Opin. Drug Saf. 2006, 5, 469–479. [Google Scholar] [CrossRef] [PubMed]
  24. Herbst, R.S.; LoRusso, P.M.; Purdom, M.; Ward, D. Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management. Clin. Lung Cancer 2003, 4, 366–369. [Google Scholar] [CrossRef] [PubMed]
  25. Sunaga, N.; Tomizawa, Y.; Yanagitani, N.; Iijima, H.; Kaira, K.; Shimizu, K.; Tanaka, S.; Suga, T.; Hisada, T.; Ishizuka, T.; et al. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer 2007, 56, 383–389. [Google Scholar] [CrossRef] [PubMed]
  26. Piraccini, B.M.; Alessandrini, A. Drug-related nail disease. Clin. Dermatol. 2013, 31, 618–626. [Google Scholar] [CrossRef] [PubMed]
  27. Donovan, J.C.; Ghazarian, D.M.; Shaw, J.C. Scarring Alopecia Associated with Use of the Epidermal Growth Factor Receptor Inhibitor Gefitinib. Arch. Dermatol. 2008, 144, 1524–1525. [Google Scholar] [CrossRef] [PubMed]
  28. Graves, J.E.; Jones, B.F.; Lind, A.C.; Heffernan, M.P. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J. Am. Acad. Dermatol. 2006, 55, 349–353. [Google Scholar] [CrossRef] [PubMed]
  29. Li, Y.Q.; Sun, H.; Xue, D. A severe dermatologic adverse effect related with gefitinib: Case report and review of the literature. J. Cancer Res. Ther. 2013, 9 (Suppl. S2), 110–113. [Google Scholar] [CrossRef]
  30. Ferrazzi, A.; Russo, I.; Pasello, G.; Alaibac, M. Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature. Exp. Ther. Med. 2016, 11, 197–200. [Google Scholar] [CrossRef]
  31. Rodriguez-Antona, C.; Savieo, J.L.; Lauschke, V.M.; Sangkuhl, K.; Drögemöller, B.I.; Wang, D.; van Schaik, R.H.N.; Gilep, A.A.; Peter, A.P.; Boone, E.C.; et al. PharmVar GeneFocus: CYP3A5. Clin. Pharmacol. Ther. 2022, 112, 1159–1171. [Google Scholar] [CrossRef]
  32. Chen, Y.-R.; Yu, X.; Xu, L.-M.; Mei, J.; Tian, M.-L.; Xu, M.; Jin, Q.-Y.; Ye, L.-B.; Yang, S.-X. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers. Xenobiotica 2024, 54, 38–44. [Google Scholar] [CrossRef] [PubMed]
  33. Kwok, W.C.; Lam, D.C.L.; Ip, M.S.M.; Tam, T.C.C.; Ho, J.C.M. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Anticancer. Drugs 2022, 33, 1139–1144. [Google Scholar] [CrossRef] [PubMed]
  34. Mckillop, D.; McCormick, A.D.; Millar, A.; Miles, G.S.; Phillips, P.J.; Hutchison, M. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005, 35, 39–50. [Google Scholar] [CrossRef] [PubMed]
  35. Mckillop, D.; Mccormick, A.D.; Miles, G.S.; Phillips, P.J.; Pickup, K.J.; Bushby, N.; Hutchison, M. In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica 2004, 34, 983–1000. [Google Scholar] [CrossRef] [PubMed]
  36. Sugiyama, E.; Umemura, S.; Nomura, S.; Kirita, K.; Matsumoto, S.; Yoh, K.; Niho, S.; Ohmatsu, H.; Tsuboi, M.; Ohe, Y.; et al. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 2015, 90, 307–313. [Google Scholar] [CrossRef] [PubMed]
  37. Gow, J.M.; Hodges, L.M.; Chinn, L.W.; Kroetz, D.L. Substrate-Dependent Effects of Human ABCB1 Coding Polymorphisms. J. Pharmacol. Exp. Ther. 2008, 325, 435–442. [Google Scholar] [CrossRef] [PubMed]
  38. Skinner, K.T.; Palkar, A.M.; Hong, A.L. Genetics of ABCB1 in Cancer. Cancers 2023, 15, 4236. [Google Scholar] [CrossRef] [PubMed]
  39. Fojo, A.T.; Ueda, K.S.D.J.; Slamon, D.J.; Poplack, D.G.; Gottesman, M.M.; Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 1987, 84, 265–269. [Google Scholar] [CrossRef] [PubMed]
  40. Mittal, B.; Tulsyan, S.; Mittal, R. The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. Pharmgenom. Pers. Med. 2016, 9, 47. [Google Scholar] [CrossRef]
  41. Gonzalez-Haba, E.; García, M.I.; Cortejoso, L.; López-Lillo, C.; Barrueco, N.; García-Alfonso, P.; Alvarez, S.; Jiménez, J.L.; Martín, M.L.; Muñóz-Fernández, M.A.; et al. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 2010, 11, 1715–1723. [Google Scholar] [CrossRef]
  42. Ma, Y.; Xin, S.; Huang, M.; Yang, Y.; Zhu, C.; Zhao, H.; Zhang, Y.; Chen, L.; Zhao, Y.; Li, J.; et al. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): A pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenom. J. 2017, 17, 325–330. [Google Scholar] [CrossRef] [PubMed]
  43. Morau, M.V.; Seguin, C.S.; Visacri, M.B.; Pincinato, E.d.C.; Moriel, P. Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis. Genes 2024, 15, 591. [Google Scholar] [CrossRef] [PubMed]
  44. Kukal, S.; Guin, D.; Rawat, C.; Bora, S.; Mishra, M.K.; Sharma, P.; Paul, P.R.; Kanojia, N.; Grewal, G.K.; Kukreti, S.; et al. Multidrug efflux transporter ABCG2: Expression and regulation. Cell. Mol. Life Sci. 2021, 78, 6887–6939. [Google Scholar] [CrossRef] [PubMed]
  45. Cusatis, G.; Gregorc, V.; Li, J.; Spreafico, A.; Ingersoll, R.G.; Verweij, J.; Ludovini, V.; Villa, E.; Hidalgo, M.; Sparreboom, A.; et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. 2006, 98, 1739–1742. [Google Scholar] [CrossRef] [PubMed]
  46. Akasaka, K.; Kaburagi, T.; Yasuda, S.; Ohmori, K.; Abe, K.; Sagara, H.; Ueda, Y.; Nagao, K.; Imura, J.; Imai, Y. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non–small-cell lung cancer. Cancer Chemother. Pharmacol. 2010, 66, 691–698. [Google Scholar] [CrossRef] [PubMed]
  47. Horsey, A.J.; Cox, M.H.; Sarwat, S.; Kerr, I.D. The multidrug transporter ABCG2: Still more questions than answers. Biochem. Soc. Trans. 2016, 44, 824–830. [Google Scholar] [CrossRef] [PubMed]
  48. Tang, L.N.; Zhang, C.L.; He, H.R.; Pan, Z.Y.; Fan, D.; He, Y.L.; You, H.S.; Li, Y.J. Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: A meta-analysis. Oncol. Targets. Ther. 2018, 11, 665–675. [Google Scholar] [CrossRef] [PubMed]
  49. Nofziger, C.; Turner, A.J.; Sangkuhl, K.; Whirl-Carrillo, M.; Agúndez, J.A.G.; Black, J.L.; Dunnenberger, H.M.; Ruano, G.; Kennedy, M.A.; Phillips, M.S.; et al. PharmVar GeneFocus: CYP2D6. Clin. Pharmacol. Ther. 2020, 107, 154–170. [Google Scholar] [CrossRef] [PubMed]
  50. Jarvis, J.P.; Peter, A.P.; Shaman, J.A. Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry. Front. Psychiatry 2019, 10, 432. [Google Scholar] [CrossRef]
  51. Suzumura, T.; Kimura, T.; Kudoh, S.; Umekawa, K.; Nagata, M.; Kira, Y.; Nakai, T.; Matsuura, K.; Yoshimura, N.; Hirata, K. Reduced CYP2D6 Function Potentiates the Gefitinib-Induced Rash in Patients with Non-Small Cell Lung Cancer. Ann. Oncol. 2012, 23, ix79. [Google Scholar] [CrossRef]
  52. Chowell, D.; Morris, L.G.T.; Grigg, C.M.; Weber, J.K.; Samstein, R.M.; Makarov, V.; Kuo, F.; Kendall, S.M.; Requena, D.; Riaz, N.; et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018, 359, 582–587. [Google Scholar] [CrossRef] [PubMed]
Pharmaceuticals 17 01040 g001
Figure 1. Adverse reactions induced by gefitinib (250 mg/day) in a 55-year-old woman. (a) Mild cutaneous adverse reactions on the face after 4 weeks of gefitinib treatment. (b) Severe cutaneous adverse reactions on the face after 10 weeks of gefitinib treatment. (c) Appearance of pustules and papules on the left side of the cheek after 10 weeks of gefitinib treatment. (d) Cutaneous adverse reactions on the face 7 d after interrupting gefitinib treatment and starting oral tetracycline (1 g twice daily) treatment. (e) Left side of the face 7 d after interrupting gefitinib treatment and starting oral tetracycline (1 g twice daily) treatment. (f) Right side of the face 7 d after interrupting gefitinib treatment and starting oral tetracycline (1 g twice daily) treatment. (g) Cutaneous adverse reactions on the face 15 d after interrupting gefitinib treatment and starting oral tetracycline treatment. (h) Left side of the face 15 d after interrupting gefitinib treatment and starting oral tetracycline treatment. (i) Right side of the face 15 d after interrupting gefitinib treatment and starting oral tetracycline treatment. (j) The face showed a serious adverse reaction 8 months after the re-introduction of gefitinib. (k) Patient abdomen exhibited mild adverse reactions 8 months after the re-introduction of gefitinib. (l) Right side of the costal region exhibited adverse reactions after the re-introduction of gefitinib. (m) Left side of the costal region exhibited adverse reactions after the re-introduction of gefitinib.
Figure 1. Adverse reactions induced by gefitinib (250 mg/day) in a 55-year-old woman. (a) Mild cutaneous adverse reactions on the face after 4 weeks of gefitinib treatment. (b) Severe cutaneous adverse reactions on the face after 10 weeks of gefitinib treatment. (c) Appearance of pustules and papules on the left side of the cheek after 10 weeks of gefitinib treatment. (d) Cutaneous adverse reactions on the face 7 d after interrupting gefitinib treatment and starting oral tetracycline (1 g twice daily) treatment. (e) Left side of the face 7 d after interrupting gefitinib treatment and starting oral tetracycline (1 g twice daily) treatment. (f) Right side of the face 7 d after interrupting gefitinib treatment and starting oral tetracycline (1 g twice daily) treatment. (g) Cutaneous adverse reactions on the face 15 d after interrupting gefitinib treatment and starting oral tetracycline treatment. (h) Left side of the face 15 d after interrupting gefitinib treatment and starting oral tetracycline treatment. (i) Right side of the face 15 d after interrupting gefitinib treatment and starting oral tetracycline treatment. (j) The face showed a serious adverse reaction 8 months after the re-introduction of gefitinib. (k) Patient abdomen exhibited mild adverse reactions 8 months after the re-introduction of gefitinib. (l) Right side of the costal region exhibited adverse reactions after the re-introduction of gefitinib. (m) Left side of the costal region exhibited adverse reactions after the re-introduction of gefitinib.
Pharmaceuticals 17 01040 g001
Table 1. Pharmacogenetic tests results.
Table 1. Pharmacogenetic tests results.
GenePatient GenotypePatient Phenotype
   CYP2D6*1/*2normal metabolizer (CNV = 2)
   CYP3A4*1/*2normal metabolizer
   CYP3A5*3/*3poor metabolizer
   ABCB1
       rs 1045642 (3435 A > C)A/A-
       rs 1128503 (c.1236A > G)G/G-
       rs 2032582 (2677 C > T/A)C/C-
   ABCG2
       rs2231142 (c.421G > T)G/T-
       rs2622604 (c.-20 + 614 T > C)C/T-
   EGFR
       rs2227983 (1562 G > A)G/G-
       rs2293347 (c.2982 C > T)C/C-
   HLA
       A/BRef/Ref-
CYP, cytochrome P450; ABCB1, adenosine triphosphate-binding cassette subfamily B member 1; ABCG2, adenosine triphosphate-binding cassette subfamily G member 2; EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; CNV, copy number variation.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Morau, M.V.; Seguin, C.S.; Perroud Junior, M.W.; Dagli-Hernandez, C.; Pincinato, E.d.C.; Moriel, P. Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile. Pharmaceuticals 2024, 17, 1040. https://doi.org/10.3390/ph17081040

AMA Style

Morau MV, Seguin CS, Perroud Junior MW, Dagli-Hernandez C, Pincinato EdC, Moriel P. Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile. Pharmaceuticals. 2024; 17(8):1040. https://doi.org/10.3390/ph17081040

Chicago/Turabian Style

Morau, Mariana Vieira, Cecilia Souto Seguin, Mauricio Wesley Perroud Junior, Carolina Dagli-Hernandez, Eder de Carvalho Pincinato, and Patricia Moriel. 2024. "Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile" Pharmaceuticals 17, no. 8: 1040. https://doi.org/10.3390/ph17081040

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop